ATLANTA
—
A
promising
new
HIV
vaccine
developed
in
Atlanta
is
taking
a
major
step
forward,
the
Atlanta
Business
Chronicle
reported
April
23.
The
vaccine,
created
by
Emory
researcher
Harriet
Robinson
and
an
Atlanta
biotech
company
called
GeoVax
Inc.,
is
moving
into
human
clinical
trials,
the
newspaper
reported.
This
will
be
the
first
time
the
entire
vaccine
has
been
tested
on
humans.
Part
of
the
vaccine
was
used
in
a
preliminary
safety
trial
in
2003,
and
it
showed
encouraging
results
in
humans.
But
the
vaccine
faces
several
rounds
of
trials,
which
are
likely
to
take
at
least
four
years.
The
vaccine
won’t
be
available
until
all
of
the
trials
are
completed
and
the
drug
gets
approval
from
the
Food
&
Drug
Administration.
Robinson
and
a
team
of
researchers
first
tested
the
vaccine
in
rhesus
monkeys
at
the
Yerkes
National
Primate
Research
Center
at
Emory
University.
In
those
trials,
the
vaccine
protected
96
percent
of
the
monkeys
for
more
than
three
and
a
half
years.
Robinson
teamed
with
pharmaceutical
veteran
Don
Hildebrand
to
start
GeoVax
to
further
develop
the
vaccine.
Sex,
tattoos
increase
HIV
risk
in
Ga.
prisons
ATLANTA
—
The
risk
of
contracting
HIV
in
Georgia’s
prison
system
increases
for
men
who
have
sex
with
men
or
get
tattoos
while
behind
bars,
but
more
than
90
percent
of
HIV-positive
prisoners
were
already
infected
with
the
virus
when
they
became
incarcerated,
according
to
a
report
from
the
Centers
for
Disease
Control
&
Prevention.
The
study
found
that
those
at
highest
risk
for
contracting
HIV
in
Georgia’s
prisons
include
men
who
have
sex
with
men;
men
who
get
a
tattoo
in
prison;
African
Americans;
inmates
older
than
26
and
those
who
have
served
more
than
five
years
of
their
sentence.
From
July
1988
through
February
2005,
of
those
male
inmates
who
were
HIV
negative
when
sentenced
but
then
contracted
HIV
while
in
prison,
42
percent
had
had
more
than
one
negative
HIV
test
before
their
HIV
diagnosis.
Physician
costs
only
account
for
2
percent
of
HIV
patient
care
NEW
YORK
—
In
caring
for
patients
at
a
university
HIV
clinic,
physician
costs
account
for
only
2
percent
of
the
annual
total
costs
per
patient,
researchers
report
in
the
April
issue
of
Clinical
Infectious
Diseases,
Reuters
reported
April
13.
Dr.
Ray
Y.
Chen
and
colleagues
at
the
University
of
Alabama
at
Birmingham
calculated
the
annual
expenditures
per
patient
with
HIV
infection
based
on
actual
health
care
use.
They
found
that
annual
costs
were
$13,885
for
HIV
patients
with
CD4
cell
counts
of
350
or
higher.
The
cost
for
HIV-infected
patients
with
CD4
cell
counts
below
50
averaged
almost
three
times
as
much.
The
researchers
found
that
the
physician
component
was
only
$359
per
patient
per
year.
Cities
spar
with
rural
areas
over
Ryan
White
funds
WASHINGTON
(AP)
—
AIDS
started
as
a
big-city
epidemic
infecting
mostly
gay
white
men,
but
now
it’s
prevalent
in
the
South
and
among
minorities.
With
hundreds
of
millions
of
dollars
at
stake,
Congress
is
attempting
for
the
first
time
since
2000
to
amend
the
Ryan
White
CARE
Act
of
1990.
"We
haven’t
seen
the
money
shifting
with
the
epidemic.
I
don’t
believe
a
person
should
be
punished
because
of
where
they
live
geographically,
and
that’s
what’s
happening,"
said
Kathie
Hiers,
head
of
AIDS
Alabama.
The
federal
law
sends
about
$2
billion
a
year
under
Ryan
White.
Congress
is
seeking
a
way
to
distribute
money
more
fairly
without
suddenly
depriving
any
one
area
of
dollars.
Wider
inpatient
testing
may
help
identify
HIV
NEW
YORK
—
New
research
supports
expanding
routine
inpatient
HIV
testing
beyond
those
who
have
traditional
risk
factors
for
the
AIDS
virus,
investigators
report
in
the
April
issue
of
Mayo
Clinic
Proceedings,
Reuters
reported
April
17.
Dr.
Jeffrey
L.
Greenwald
of
the
Boston
Medical
Center
looked
at
the
percentage
of
inpatients
who
tested
positive
for
HIV
as
part
of
routine
inpatient
testing
who
might
not
otherwise
have
been
spotted
had
such
testing
not
been
offered.
Among
a
total
of
243
subjects,
81
who
tested
positive
and
81
who
tested
negative
by
the
inpatient
service
were
compared
with
81
who
tested
positive
in
emergency
rooms.
Patients
who
tested
HIV
positive
via
inpatient
testing
had
more
advanced
disease
than
those
identified
as
HIV
positive
as
outpatients.